

VALEANT PHARMACEUTICALS INTERNATIONAL

Form 8-K

May 07, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of the earliest event reported): **May 7, 2008**

**Valeant Pharmaceuticals International**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation or organization)

**1-11397**

(Commission File Number)

**33-0628076**

(I.R.S Employer  
Identification No.)

**One Enterprise**

**Aliso Viejo, California 92656**

(Address of principal executive offices) (Zip Code)

**(949) 461-6000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 2.02 Results of Operations and Financial Condition

Item 9.01 Financial Statements and Exhibits.

SIGNATURES

INDEX TO EXHIBITS

EXHIBIT 99.1

EXHIBIT 99.2

---

**Table of Contents**

**Item 2.02 Results of Operations and Financial Condition**

On May 7, 2008, Valeant Pharmaceuticals International (the Company) issued a press release announcing results of operations for the quarter ended March 31, 2008 and certain other financial information as of and for the quarter ended March 31, 2008. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference. On May 7, 2008, the Company also made available on its website ([www.valeant.com](http://www.valeant.com)) supplemental financial information for the quarterly periods ended March 31, 2007, June 30, 2007, September 30, 2007, and December 31, 2007 and the comparable periods for 2006, including certain non-GAAP financial measures. A copy of the information posted on the website is attached as Exhibit 99.2 to this report and is incorporated herein by this reference.

The information in this Item 2.02, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibits 99.1 and 99.2 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press release dated May 7, 2008.

99.2 Information made available on the Company's website on May 7, 2008.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VALEANT PHARMACEUTICALS  
INTERNATIONAL

Date: May 7, 2008

By: /s/ Peter J. Blott  
Peter J. Blott  
Executive Vice President  
and Chief Financial Officer

---

**Table of Contents**

**INDEX TO EXHIBITS**

99.1 Press release dated May 7, 2008.

99.2 Information made available on the Company's website on May 7, 2008.